Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

Research Base: Southwest Oncology Group
NCT ID: NCT03723928
NCI Protocol Number: SWOG-S1703
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Condition

Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29

Trial Type

Cancer Care Delivery Research (CCDR)

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP